Antitumor activity of α-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production

Oncology Research

Volumn 10, Issue 11-12, 1998, Pages 561-562

  Nakagawa, Ryusuke ^a   Motoki, Kazuhiro ^a   Nakamura, Hiromi ^a   Ueno, Hitomi ^a   Iijima, Rieko ^a   Yamauchi, Akira ^b   Tsuyuki, Shigeru ^b   Inamoto, Takashi ^b   Koezuka, Yasuhiko ^a  

^a KIRIN BREWERY CO LTD   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Galactosylceramide; Glycolipid; Hepatic metastasis; Krn7000; ; Nkt cells

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ANTINEOPLASTIC AGENT; CYTOKINE; GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4;

ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; FEMALE; LIVER TUMOR; LUNG TUMOR; MELANOMA; METABOLISM; METASTASIS; MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; FEMALE; GALACTOSYLCERAMIDES; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-4; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MELANOMA; MICE;

EID: 0032242177     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Oberfield, R. A.; Mccaffrey, J. A.; Polio, J. Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary. Cancer 44:414-423; 1979.
2. Carter, S. K. The adjuvant therapy of large-bowel cancer. In: Carter, S.; Glatstein, E.; Livingston, R. B., eds. Principles of cancer treatment. New York: McGraw-Hill; 1982:379-401.
3. Nakagawa, R.; Motoki, K.; Ueno, H.; Iijima, R.; Nakamura, H.; Kobayashi, E.; Shimosaka, A.; Koezuka, Y. Treatment of hepatic metastasis of the Colon26 adenocarcinoma with α-galactosylceramide, KRN7000. Cancer Res. 58:1202-1207; 1998.
4. Yamaguchi, Y.; Ueno, H.; Maeda, K.; Motoki, K.; Kobayashi, E.; Inoue, H.; Fukushima, H.; Koezuka, Y. Enhancing effects of (2S, 3S, 4R)-1-O-(α-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4- octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol. Res. 8:399-407; 1996.
5. Kawano, T.; Cui, J.; Koezuka, Y.; Toura, I.; Kaneko, Y.; Motoki, K.; Ueno, H.; Nakagawa, R.; Sato, H.; Kondo, E.; Koseki, H.; Taniguchi, M. CD1d-restricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science 278:1626-1629; 1997.
6. Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; Yamaji, K.; Kobayashi, E.; Fukushima, H.; Koezuka, Y. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J. Med. Chem. 38:2176-2187; 1995.
7. Goossens, P. L.; Jouin, H.; Marchal, G.; Milon, G. Isolation and flow cytometric analysis of the free lymphomyeloid cells present in murine liver. J. Immunol. Methods 132:137-144; 1990.
8. Talmadge, J. E.; Herberman, R. B.; Chirigos, M. A.; Maluish, A. E.; Schneider, M. A.; Adams, J. S.; Philips, H.; Thurman, G. B.; Varesio, L.; Long, C.; Oldham, R. K.; Wiltrout, R. H. Hypore-sponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2. J. Immunol. 135:2483-2491; 1985.
9. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J. Immunol. 154:4333-4340; 1995.
10. Kobayashi, E.; Motoki, K.; Uchida, T.; Fukushima, H.; Koezuka, Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7:529-534; 1995.
11. Eisenthal, A.; Lafreniere, R.; Lefor, A. T.; Rosenberg S. A. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res. 47:2771-2776; 1987.
12. + cells: New clues to their origin, specificity, and function. J. Exp. Med. 182:633-638; 1995.
13. + T cells: A new family of T cells. Immunol. Today 17:71-76; 1996.
14. Seki, S.; Takeda, K. The antitumor function of extrathymic T cells with an NK cell marker in the mouse liver and their putative counterpart in humans. Acta Med. Biol. 44:117-133; 1996.
15. Cui, J.; Shin, T.; Kawano, T.; Sato, H.; Kondo, E.; Toura, I.; Kaneko, Y.; Koseki, H.; Kanno, M.; Taniguchi, M. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Sience 278:1623-1626; 1997.
16. Saito, M.; Ichimura, O.; Kataoka, M.; Moriya, Y.; Ueno, K.; Sugawara, Y.; Nanjo, M.; Ishida, N. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation. Cancer Immunol. Immunother. 22:161-168; 1986.
17. Rosenstein, M.; Yron, I.; Rosenberg, S. A. Lymphokine activated killer cells: Lysis of fresh syngeneic NK-resistant fresh murine tumor cells by lymphocytes cultured in interleikin-2. Cancer Res. 44:1946-1953; 1984.
18. + NKT lymphocytes. J. Immunol. 161:3271-3281; 1998.
19. Minato, N.; Reid, L.; Cantor, H.; Lengyel, P.; Bloom, B. R. Mode of regulation of natural killer cell activity by interferon. J. Exp. Med. 152:124-138; 1980.
20. + T cells express CD40 ligand and induce antigen-presenting cells to produce IL-12. J. Immunol. (in press).
21. Kawano, T.; Cui, J.; Koezuka, Y.; Toura, I.; Kaneko, Y.; Sato, H.; Kondo, E.; Harada, M.; Koseki, H.; Nakayama, T.; Tanaka, Y.; Taniguchi, M. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl. Acad. Sci. USA 95:5690-5693 1998.
22. Hong, S.; Scherer, D. C.; Singh, N.; Mendriratta, S. K.; Serizawa, I.; Koezuka, Y.; Van Kaer, L. Lipid antigen presentation in the immune system: Lessons learned from CD1d knockout mice. Immunol. Rev. (in press).
23. Mendiratta, S. K.; Martin, W. D.; Hong, S.; Boesteanu, A.; Joyse, S.; Van Kaer, L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6:469-477; 1998.
24. Zen, H. J.; Hurd, S.; Storkus, W. J.; Lotze, M. T. Interleukin12 promotes the proliferation and cytolytic maturation of immune effectors: Implications for the immunotherapy of cancer. J. Immunother. 14:155-161; 1993.
25. Spada, F.; Koezuka, Y.; Porcelli, S. A. CD1d-restricted recognition of synthetic glycolipid antigens by human NKT cells. J. Exp. Med. 188:1529-1534; 1998.
26. Brossay, L.; Chioda, M.; Burdin, N.; Koezuka, Y.; Casorati, G.; Dellabona, P.; Kronenberg, M. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1521-1528; 1998.
27. Couedel, C.; Reyrat, M.-A.; Brossay, L.; Koezuka, Y.; Porcelli, S.; Davodeau, F.; Bonneville, M. Diverse CD1d-restricted reactivity patterns of human T cells bearing invariant AV24BV11 T cell receptors. Eur. J. Immunol. 28:4391-4397; 1998.
28. Nieda, M.; Nicol, A.; Koezuka, Y.; Kikuchi, A.; Nakamura, H.; Takahashi, T.; Furukawa, H.; Yabe, T.; Ishikawa, Y.; Tadokoro, K.; Juji, T. Activation of human Vα24 NKT cells by an α-galactosylceramide in a CD1d-restricted and Vα24 TCR-mediated manner. Hum. Immunol. 60:10-19, 1999.